Dramatic shift to precision lipidology in ASCVD prevention.
The 2026 ACC/AHA guideline on dyslipidemia introduces significant changes in secondary prevention of atherosclerotic cardiovascular disease (ASCVD), focusing on individualized, earlier, and intensified lipid-lowering strategies beyond low-density lipoprotein cholesterol (LDL-C). New guidelines recommend lower targets for LDL-C (<55 mg/dL) and non-high-density lipoprotein cholesterol (non-HDL-C) (<85 mg/dL), use of non-statin therapies, and structured lipid monitoring. These guidelines suggest a shift towards precision lipidology with emphasis on reducing residual cardiovascular risk and managing statin-attributed muscle symptoms, highlighting the need for pharmacists to support individualized patient care. New ACC/AHA guidelines prioritize precision lipidology with lower lipid targets and expanded non-statin options for ASCVD prevention.
Authors: Siddiqi AK, Jacob J, Khan MS, Kulkarni A
Citation: Siddiqi AK, Jacob J, Khan MS, et al. Top 10 Concepts in Secondary ASCVD Prevention From the 2026 ACC/AHA Dyslipidemia Guideline: What Is New and Why It Matters. Current atherosclerosis reports. 2026;28(1). doi:10.1007/s11883-026-01465-5
Article Links: PubMed · Journal / DOI
The full analysis for this article is being written and reviewed. Every analysis is checked by a licensed pharmacist before it publishes.